In particular, there is currently no consensus to determine which advanced melanoma patient will benefit from immune checkpoint blockers such as PD-L1 expression, mismatch repair deficiency, and tumor infiltrating lymphocytes (TILs), which all failed to be predictors in the clinical setting. Here, CD274 is linked to neoplasm.